C4 Therapeutics Inc. Common Stock (CCCC)

FairStock Score: 63/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach C4 Therapeutics as a Graham-style analyst would: first ask whether the business earns money, then whether the price offers protection. The answer from the filed figures is not encouraging. In fiscal year 2025, the year ended 2025-12-31, revenue was $35.9 million and net loss was $105.0 million. In fiscal year 2024, revenue was $35.6 million and net loss was $105.3 million. In fiscal year 2023, revenue was $20.8 million and net loss was $132.5 million. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $6.6 million and net loss was $23.6 million, or diluted EPS -$0.18. The company remains clinical-stage and has not earned a profit in the last four years; that is why the computed Lynch category is none.

In plain English: C4 Therapeutics is a clinical-stage biotech trying to develop new cancer drugs, including an oral medicine for multiple myeloma. It has no profits, brings in only small revenue, and is spending more cash than it takes in, so the business looks financially weak today. At the 2026-10-13 close of $2.78 and a $342 million market value, the price does not look clearly cheap given the losses, and because there are no earnings, it is hard to call it fair or expensive using normal earnings measures.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer